Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Non-Current Debt (2018 - 2021)

Rein Therapeutics filings provide 3 years of Non-Current Debt readings, the most recent being $55000.0 for Q1 2021.

  • For the quarter ending Q1 2021, Non-Current Debt changed N/A year-over-year to $55000.0, compared with a TTM value of $55000.0 through Mar 2021, changed N/A, and an annual FY2020 reading of $219000.0, changed N/A over the prior year.
  • Non-Current Debt hit $55000.0 in Q1 2021 for Rein Therapeutics, down from $219000.0 in the prior quarter.
  • The five-year high for Non-Current Debt was $5.3 million in Q4 2018, with the low at $55000.0 in Q1 2021.
  • Median Non-Current Debt over the past 3 years was $336000.0 (2020), compared with a mean of $2.1 million.